Acquisition Expansion Since its acquisition by Catalent in 2016, Pharmatek has benefited from expanded resources and capabilities, positioning it as a valuable partner for pharmaceutical companies seeking comprehensive development and manufacturing support.

Specialized Capabilities Pharmatek's expertise in supporting highly potent and cytotoxic compounds presents a strategic opportunity to engage clients requiring specialized cytotoxic drug development and manufacturing solutions.

Client-Centric Approach With its focus on quality science and systems, Pharmatek appeals to organizations prioritizing high standards in early-stage development, making it a compelling partner for clients aiming to de-risk their drug pipelines.

Market Positioning Operating in the mid-market segment with revenue between 25M and 50M and a skilled workforce, Pharmatek offers a niche for tailored, high-quality services that can be leveraged to build long-term customer relationships.

Industry Trends Given the increasing demand for complex molecule and cytotoxic drug manufacturing, there is a growth opportunity to expand service offerings and capture more market share within the biotech and pharma sectors.